4/7
04:39 pm
itos
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Finance]
Medium
Report
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Finance]
4/7
04:30 pm
itos
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
Medium
Report
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
3/6
11:54 am
itos
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock, down previously from $25.00.
Medium
Report
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock, down previously from $25.00.
3/6
07:12 am
itos
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates [Yahoo! Finance]
Medium
Report
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates [Yahoo! Finance]
3/6
07:01 am
itos
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
Medium
Report
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
3/6
07:00 am
itos
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
Medium
Report
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
3/5
04:43 pm
itos
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Finance]
Medium
Report
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Finance]
3/5
04:30 pm
itos
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
Medium
Report
iTeos to Highlight Preclinical Data on First-In-Class EOS-984 Targeting ENT1 at the American Association for Cancer Research Annual Meeting 2024
3/1
07:00 am
itos
iTeos to Participate in Upcoming Investor Conferences
Medium
Report
iTeos to Participate in Upcoming Investor Conferences
2/26
07:52 am
itos
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength? [Yahoo! Finance]
Low
Report
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength? [Yahoo! Finance]
2/1
03:06 am
itos
Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation [Yahoo! Finance]
Low
Report
Launch of GIO Therapeutics, founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation [Yahoo! Finance]